This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Novel Transdermal Delivery Formulation of the Monoamine Oxidase Inhibitor Selegiline Nearing Release for Treatment of Depression

Michael E. Thase, MD

Published: April 15, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

A novel formulation of the monoamine oxidase inhibitor (MAOI) selegiline has been approved by the U.S. Food and Drug Administration (FDA) for treatment of depression and should be introduced at some point in the spring or early summer of 2006. Marketing of selegiline coincidently occurs almost 50 years after Nathan Kline and colleagues first recognized the therapeutic effects of the first MAOI, iproniazid.1 Administered via a skin patch, selegiline transdermal delivery system (TDS; brand name: EMSAM; manufacturer: Somerset Pharmaceuticals and distributed by Bristol-Myers Squibb Pharmaceuticals) will be the first new MAOI to be introduced in the United States for the indication of depression in more than 30 years.’ ‹’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 67

Quick Links: